TAK 779

Also Known As:

N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride; N-((4-(((6,7-dihydro-2-(4-methylphenyl)-5H-benzocyclohepten-8-yl)carbonyl)amino)phenyl)methyl)tetrahydro-N,N-dimethyl-2H-pyran-4-aminium chloride; TAK-779

Networked: 27 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fujiwara, Hiromi: 3 articles (12/2005 - 07/2002)
2.	Imanishi, Takeshi: 3 articles (12/2005 - 07/2002)
3.	Ono, Shiro: 2 articles (12/2009 - 02/2003)
4.	Yang, Yi-Fu: 2 articles (12/2009 - 02/2003)
5.	Matsushima, Kouji: 2 articles (08/2005 - 07/2002)
6.	Gao, Ping: 2 articles (02/2003 - 07/2002)
7.	Hamaoka, Toshiyuki: 2 articles (02/2003 - 07/2002)
8.	Obika, Satoshi: 2 articles (02/2003 - 07/2002)
9.	Chen, Shan: 1 article (01/2022)
10.	Dai, Shuangshuang: 1 article (01/2022)

Related Diseases

1.	Atherosclerosis 12/01/2005 - "TAK-779 treatment may be especially beneficial for young HIV patients as they face lifelong treatment, and this drug impairs atherogenesis." 12/01/2005 - "TAK-779 treatment of low-density lipoprotein receptor-deficient mice did not elevate the levels of atherogenic lipoproteins, whereas it dramatically reduced atherosclerosis in the aortic root and in the carotid arteries. " 12/01/2005 - "HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice." 12/01/2005 - "We investigated whether the HIV entry inhibitor TAK-779 affects lipoprotein levels and atherogenesis in low-density lipoprotein receptor-deficient mice. "
2.	HIV Infections (HIV Infection) 06/04/2008 - "Free SDC-1721 had no inhibitory effect on HIV infection; however, the (SDC-1721)-gold nanoparticle conjugates displayed activity comparable to that of TAK-779. " 10/01/2016 - "This study assessed the effect of temporarily dampening the chemokine receptor CXCR3 and CCR5 after vaccination on host immune responses by the administration of TAK-779, a small molecule CXCR3 and CCR5 antagonists commonly used to inhibit HIV infection. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 07/05/2005 - "In this study, we show that M-tropic R5 viruses isolated from individuals with acquired immunodeficiency syndrome (late R5 viruses) require lower levels of CD4/CCR5 expression for entry, have decreased sensitivity to inhibition by the entry inhibitors TAK-779 and T-20, and have increased sensitivity to neutralization by the Env MAb IgG1b12 compared with non-M-tropic R5 viruses isolated from asymptomatic, immunocompetent individuals (early R5 viruses). " 01/01/2012 - "The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. "
4.	Cystitis 01/01/2022 - "Therefore, in this study, we analyzed the GSE11783 sequencing data of IC/BPS patients and investigate the role and mechanism of CXCL13/CXCR5 axis and TAK-779 in the mouse model of experimental autoimmune cystitis (EAC). "
5.	Asthma (Bronchial Asthma) 04/01/2008 - "The aim of the present study was to investigate the role of CCR5 and CXCR3 in allergen-induced acute asthma and to determine whether a novel small-molecule compound, TAK-779, targeting CCR5 and CXCR3 can attenuate allergic airway responses. " 04/01/2008 - "These data demonstrate that blockade of CC chemokine receptor 5 and CXC chemokine receptor 3 using TAK-779, a synthetic nonpeptide compound, can prevent the development of asthma features in a mouse model. "

Related Drugs and Biologics

1.	LDL Receptors (LDL Receptor)
2.	Lipoproteins (Lipoprotein)
3.	Chemokine Receptors
4.	Chlorides
5.	Carbon
6.	Allergens
7.	Pyrans
8.	Peptides (Polypeptides)
9.	Enfuvirtide (Fuzeon)
10.	Chemokine CCL3

Related Therapies and Procedures

1.	Intravenous Injections
2.	Immunotherapy